Seed Grant Success Story
Karmanos Asfar Azmi, Ph.D., secures R01 grant for research into treating metastatic pancreatic cancer
University of Michigan | Howard Crawford Laboratories
In turn, the tumor cells instruct the macrophages to also make PD-L1. In an attempt to disrupt this cycle, Dr. Crawford has identified one of the primary molecules the macrophages use to turn on tumor cell PD-L1, known as HBEGF. Meanwhile, Dr. Lyssiotis has found that tumor cell metabolites are responsible for telling the macrophages to make PD-L1. With this knowledge in hand, Dr. Frankel, a surgeon who specializes in immunotherapy research, is involved in translating these observations to the clinic, combining immune checkpoint inhibitors with therapies to disrupt the cellular crosstalk responsible for establishing the immunosuppressive environment in preclinical models of human pancreatic cancer.
Immunotherapy Team Members
Marina Pasca di Magliano, PhD
Costas Lyssiotis, Phs
Timothy Frankel, MD